CareValidate Unveils Expanded Hormone Replacement Therapy Program

CareValidate, a compliance infrastructure company for telehealth brands, announced Thursday that it is launching an expanded menopause/perimenopause hormone replacement therapy pathway.

The company helps digital health companies, retailers, and wellness brands launch and scale virtual care. It offers a licensed provider network, pharmacy fulfillment, and lab diagnostics across a variety of programs, including weight loss, longevity, dermatology, and erectile dysfunction.

With the expanded HRT pathway, CareValidate’s clients can launch hormone replacement offerings—such as progesterone and estradiol—while relying on the company’s provider network and pharmacy fulfillment. HRT is frequently used to treat menopause and replaces declining estrogen and progesterone levels.

“Importantly, menopause care isn’t a one-time prescription,” said Dr. Jiten Chhabra, co-founder and chief medical officer of CareValidate. “Women’s needs change over time, and CareValidate’s infrastructure is designed to support ongoing relationships, proactive follow-up, and treatment adjustments when clinically indicated. The objective is to make healthcare feel less like a series of disconnected transactions and more like having a dedicated care team looking after each patient.”

A major differentiator of the expanded offering is CareValidate’s AI-powered care agents, Chhabra noted. These agents act as 24/7 personal healthcare concierges and help patients schedule appointments, keep medical records up to date, coordinate follow-ups, and navigate care.

“Rather than requiring patients to manage every step themselves, the agents help anticipate their needs and ensure important aspects of their care don’t fall through the cracks, while clinical decisions remain with licensed healthcare professionals,” Chhabra stated.

Historically, misinformation has created significant barriers to accessing HRT. A 2002 study falsely linked the medication to an increased risk of breast cancer. This study has since been debunked, and in 2025, the FDA announced that it is removing black box warning labels from menopausal HRT products.

Despite these advances, women continue to struggle to access the treatment they need for menopause. About 80% of menopausal women experience hot flashes or night sweats, according to the Menopause Society. A Mayo Clinic study estimates that menopause-related symptoms cost the U.S. approximately $1.8 billion in lost work time.

“Our overarching goal is to help more people access better healthcare, faster. In women’s health, that means enabling our partners to reach more patients, reduce unnecessary barriers to care, and support safe, evidence-based treatment over time,” Chhabra said. “We also want to raise the standard of care in cash-pay telehealth. Patients should expect the same commitment to clinical oversight, safety, privacy, and continuity of care whether they use insurance or pay directly.”

Photo: Toa55, Getty Images

Source link